Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Assets (2019 - 2025)

Historic Current Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $206.9 million.

  • C4 Therapeutics' Current Assets fell 2428.89% to $206.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.9 million, marking a year-over-year decrease of 2428.89%. This contributed to the annual value of $257.8 million for FY2024, which is 494.93% down from last year.
  • As of Q3 2025, C4 Therapeutics' Current Assets stood at $206.9 million, which was down 2428.89% from $224.7 million recorded in Q2 2025.
  • C4 Therapeutics' Current Assets' 5-year high stood at $477.6 million during Q2 2021, with a 5-year trough of $206.9 million in Q3 2025.
  • Moreover, its 5-year median value for Current Assets was $278.5 million (2023), whereas its average is $293.2 million.
  • In the last 5 years, C4 Therapeutics' Current Assets skyrocketed by 9734.16% in 2021 and then tumbled by 3333.52% in 2022.
  • Quarter analysis of 5 years shows C4 Therapeutics' Current Assets stood at $325.7 million in 2021, then dropped by 11.71% to $287.6 million in 2022, then fell by 5.69% to $271.2 million in 2023, then fell by 4.95% to $257.8 million in 2024, then decreased by 19.75% to $206.9 million in 2025.
  • Its last three reported values are $206.9 million in Q3 2025, $224.7 million for Q2 2025, and $232.5 million during Q1 2025.